Zalutumumab in Patients With Non-curable Head and Neck Cancer

NCT00382031 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

286

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer
Squamous Cell Cancer

Interventions

DRUG: Zalutumumab
OTHER: Control

Sponsor

Genmab